Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults

HIV Clinical Trials

Volumn 12, Issue 5, 2011, Pages 275-276

  Cooper, Curtis ^a   Thorne, Anona ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Canadian HIV Trials Network   (Canada)

Author keywords

HIV; immunogencity; influenza; vaccine; vitamin D

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE; VITAMIN D;

ADULT; ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SEROCONVERSION; VIRUS STRAIN; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; DIETARY SUPPLEMENTS; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SEASONS; TREATMENT OUTCOME; VITAMIN D; YOUNG ADULT;

EID: 84255169443     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1205-275     Document Type: Article

References (10)

1. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134(6):1129-1140. (Pubitemid 44614932)
2. Kriesel JD, Spruance J. Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Vaccine. 1999;17(15-16):1883-1888. (Pubitemid 29172356)
3. Chadha MK, Fakih M, Muindi J, et al. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. Prostate. 2010;71(4):368-372.
4. Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007;45(2):234-240. (Pubitemid 47041016)
5. Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunoDeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis. 2000;31(2):604-606.
6. Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis. 2009;48(10):1402-1412.
7. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18(26):3040-3049. (Pubitemid 30303809)
8. Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS. Patterns of use, expenditures, and perceived Efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med. 1998;158(20):2257-2264. (Pubitemid 28512500)
9. Josephs JS, Fleishman JA, Gaist P, Gebo KA. Use of complementary and alternative medicines among a multistate, multisite cohort of people living with HIV/AIDS. HIV Med. 2007;8(5):300-305. (Pubitemid 46901529)
10. Cooper C, Thorne A, Klein M, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One. 2011;6(3):e17758.